106 related articles for article (PubMed ID: 16330421)
1. Hypoxia-simulating agents selectively stimulate arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Tamm I
Haematologica; 2005 Dec; 90(12):1585A. PubMed ID: 16330421
[No Abstract] [Full Text] [Related]
2. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
[TBL] [Abstract][Full Text] [Related]
3. Curing APL: differentiation or destruction?
Kogan SC
Cancer Cell; 2009 Jan; 15(1):7-8. PubMed ID: 19111876
[TBL] [Abstract][Full Text] [Related]
4. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Guo W; Wang H; Zhao W
Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
[TBL] [Abstract][Full Text] [Related]
5. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
6. [Effects of arsenic trioxide on K562 cells stably expressing two promyelocytic leukemia-specific fusion proteins].
Zhou L; Chen G; Pan L
Zhonghua Yi Xue Za Zhi; 2000 Apr; 80(4):297-300. PubMed ID: 11798775
[TBL] [Abstract][Full Text] [Related]
7. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
8. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
[TBL] [Abstract][Full Text] [Related]
9. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
10. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
11. Overcoming treatment resistance in acute promyelocytic leukemia and beyond.
Fung TK; So CW
Oncotarget; 2013 Aug; 4(8):1128-9. PubMed ID: 23934744
[No Abstract] [Full Text] [Related]
12. Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia.
Kizaki M; Muto A; Kinjo K; Ueno H; Ikeda Y
J Natl Cancer Inst; 1998 Dec; 90(24):1906-7. PubMed ID: 9862629
[No Abstract] [Full Text] [Related]
13. Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
Wang HX; Duan LN; Ji SQ; Guo ZK
Leuk Lymphoma; 2006 Jul; 47(7):1438-40. PubMed ID: 16923589
[No Abstract] [Full Text] [Related]
14. APL, a model disease for cancer therapies?
de Thé H; Chelbi-Alix MK
Oncogene; 2001 Oct; 20(49):7136-9. PubMed ID: 11704841
[No Abstract] [Full Text] [Related]
15. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
16. Hot on the TRAIL of acute promyelocytic leukemia.
Zelent A
Nat Med; 2001 Jun; 7(6):662-4. PubMed ID: 11385499
[No Abstract] [Full Text] [Related]
17. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
Zhu J; Lallemand-Breitenbach V; de Thé H
Oncogene; 2001 Oct; 20(49):7257-65. PubMed ID: 11704854
[TBL] [Abstract][Full Text] [Related]
18. [In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)].
Cai X; Jia P; Shi X
Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):339-41. PubMed ID: 11189513
[TBL] [Abstract][Full Text] [Related]
19. Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.
Nichol JN; Garnier N; Miller WH
Best Pract Res Clin Haematol; 2014 Mar; 27(1):19-31. PubMed ID: 24907014
[TBL] [Abstract][Full Text] [Related]
20. Acute promyelocytic leukemia--weapons of mass differentiation.
Licht JD
N Engl J Med; 2009 Feb; 360(9):928-30. PubMed ID: 19246367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
